CRISPR Therapeutics AG trades publicly on the NASDAQ Global Select Market under the ticker symbol CRSP. As a pioneering clinical-stage biopharmaceutical enterprise, the company focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. Investors tracking the biotechnology and gene-editing sector utilize the CRSP ticker to monitor its ongoing clinical trials, regulatory approvals, and financial performance updates.